ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 154 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $235,000 | -19.8% | 5,340 | -10.0% | 0.00% | 0.0% |
| Q1 2021 | $293,000 | -34.9% | 5,932 | -44.5% | 0.00% | -50.0% |
| Q4 2020 | $450,000 | -6.4% | 10,680 | +1.6% | 0.00% | -20.0% |
| Q3 2020 | $481,000 | -8.6% | 10,510 | +0.3% | 0.01% | -16.7% |
| Q2 2020 | $526,000 | -1.1% | 10,478 | +1.3% | 0.01% | -14.3% |
| Q1 2020 | $532,000 | +18.2% | 10,342 | +42.1% | 0.01% | +75.0% |
| Q4 2019 | $450,000 | +103.6% | 7,280 | +97.7% | 0.00% | +100.0% |
| Q3 2019 | $221,000 | +820.8% | 3,683 | +1215.4% | 0.00% | – |
| Q2 2019 | $24,000 | -7.7% | 280 | +1.8% | 0.00% | – |
| Q1 2019 | $26,000 | +30.0% | 275 | -4.5% | 0.00% | – |
| Q4 2018 | $20,000 | -9.1% | 288 | +9.5% | 0.00% | – |
| Q3 2018 | $22,000 | +57.1% | 263 | +115.6% | 0.00% | – |
| Q2 2018 | $14,000 | +75.0% | 122 | +16.2% | 0.00% | – |
| Q1 2018 | $8,000 | -27.3% | 105 | -44.1% | 0.00% | – |
| Q4 2017 | $11,000 | – | 188 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |